Columbus backs Accipiter with $12.7M seed

Columbus Venture Partners has joined a syndicate backing Accipiter Biosciences in a seed financing that will accelerate the startup’s work on engineered, multifunctional protein therapeutics. The round totals $12.7 million, led by strategic and specialist investors alongside biopharma partners that have already signed development pacts with the company.

Founded in Seattle, Accipiter Biosciences combines computational design with high-throughput laboratory validation to create proteins built from scratch. These de novo molecules are intended to integrate several mechanisms of action into a single stable construct — an approach the company dubs a move beyond evolutionary templates toward ‘‘post‑evolutionary biologics’’. Management argues the model could replace multi‑drug combinations in some indications by delivering coordinated activity in one therapeutic.

The seed was co-led by industry players including Takeda and Flying Fish Partners, with participation from investors such as Columbus Venture Partners, Cercano Capital, Washington Research Foundation, Alexandria Venture Investments, Pack Ventures and Argonautic Ventures. In addition to equity, the company has secured alliance agreements with major pharma: a license deal with Pfizer that carries potential development milestones and royalties, and a multitarget collaboration with Kite Pharma (Gilead) focused on cell‑therapy targets.

Under the Pfizer arrangement Accipiter received an upfront payment and could earn more than $330 million in milestones, highlighting how early‑stage computational platforms can be de‑risked by industrial partnerships. Jeffrey Settleman, Pfizer’s CSO for oncology R&D, described the collaboration as an opportunity to tackle complex therapeutic challenges with designer biologics that were previously out of reach. Heather Gorham of Flying Fish Partners framed the seed as proof that computation is expanding what can be achieved biologically.

The new capital will primarily fund two preclinical programs in immunology and oncology while strengthening Accipiter’s design and screening stack. For venture investors, the combination of an algorithmic discovery engine and early pharma commitments is attractive: it shortens validation cycles and provides structured value‑sharing via upfronts, milestones and royalties. Still, the path to clinic presents familiar hurdles — manufacturing complexity, immunogenicity assessment and regulatory scrutiny of novel protein modalities.

From a market perspective, the transaction sits within a broader surge of venture interest in AI‑enabled and computational biology startups. Early rounds that would once have been a few million dollars are increasingly topping the low‑double‑digit millions as founders seek to build both software and wet‑lab capabilities before clinical entry. Strategic alliances with established pharmaceutical companies now act as important signals of technical credibility and commercialization potential.

Matthew Bick, Accipiter’s cofounder and CEO, said the funding will accelerate the company’s objective of delivering single‑molecule therapies that tackle multiple pathways simultaneously. For Columbus Venture Partners, the investment reflects a deliberate strategy: backing frontier computational bioscience teams that combine deep tech and translational ambition, positioning them to shape the next wave of therapeutic innovation.